Navigation Links
Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
Date:9/23/2007

oval of the metastatic lesions (R0 resection) was achieved in 170 patients, an impressive success rate of 79%. The best outcomes as expected were achieved in the subgroup of patients with metastatic disease confined to the liver only (n=704). In this subgroup, 102 (14.5%) patients underwent surgical removal of their liver metastases in curative intent with successful complete (R0) resection achieved in 81 patients.

No increase in wound-healing complications or bleeding incidents was observed compared with historical controls underlining the favourable safety profile of Avastin in this setting.

Colorectal cancer is the third most common cancer with approximately one million new cases worldwide every year. It is estimated that over 50% of people diagnosed with colorectal cancer will die of the disease(1).

About First BEAT

First BEAT is an international phase IV trial which has enrolled 1965, community based patients from 41 countries worldwide. Patients diagnosed with unresectable metastatic disease received Avastin in combination with standard first line chemotherapy; the most common regimens were FOLFOX, XELOX, FOLFIRI and Xeloda (capecitabine). The dose of Avastin used was equivalent to 2.5 mg/kg/week (5 mg/kg every 2 weeks with 5-FU-based regimens and 7.5 mg/kg every 3 weeks with capecitabine-based regimens).

First BEAT completed recruitment in February 2006. The primary endpoint was safety. General efficacy and surgery with curative intent were preplanned secondary endpoints and data were collected in a prospective fashion. Efficacy data from the BEAT trial are continuing to be evaluated with further data presentations expected at upcoming oncology conferences.

Additional information

- Roche in Oncology: http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf

- Roche Health Kiosk, Cancer:

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
2. FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer
3. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
4. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
5. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
6. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
7. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
8. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 10 million older Americans suffer from depression, often brought ... new research a project that followed the lives ... found that Internet use among the elderly can ... percent. , "That,s a very strong effect," said Shelia ... studies and media who led the project. "And it ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... may result from the body overshooting as it tries ... suggests new research// from the University of Massachusetts Amherst ... to a different time zone, the researchers recommend advancing ... allowing the body’s clocks to remain coordinated. The work ...
... pressure to resolve apparent obstructive sleep apnea may result ... ,Timothy Morgenthaler, M.D., of the Mayo Clinic, and ... reports that complex sleep apnea syndrome may cause a ... and neurologic causes. ,According to the researchers ...
... by mothers during pregnancy may heighten asthma risk in their ... of the department of environmental and occupational medicine at the ... This study was based on the findings of an earlier ... that kids at the age of 2, whose mothers had ...
... inhibitor 'Rofecoxib' might be effective in controlling the ... a new, 'A Randomized Trial of Rofecoxib for ... Gastroenterology, the journal for the members of the ... cuts the risk of colorectal adenomas. The findings ...
... NHS Quality Improvement Scotland have expressed concern over the ... their pap smears done regularly.// They feel that health ... give out importance of smears in preventing cervical cancer. ... take part in this highly successful screening programme," a ...
... Weizmann Institute's Plant Sciences Department conducted a study to ... in diverse climates like Antarctica and hot springs.// The ... two amino acids made a difference in the ability ... high degree of heat. The study appears in the ...
Cached Medicine News:Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 2Health News:Model of Internal Clocks Reveals How Jet Lag Disrupts the System 3Health News:Complex Apnea May Explain Sleepless Nights 2Health News:Complex Apnea May Explain Sleepless Nights 3Health News:Complex Apnea May Explain Sleepless Nights 4Health News:Intake of vitamin E during pregnancy influences asthma risk in kids 2Health News:Risk Of Colorectal Polyps Recurrence Can Be Controlled By Rofecoxib 2Health News:Risk Of Colorectal Polyps Recurrence Can Be Controlled By Rofecoxib 3Health News:Risk Of Colorectal Polyps Recurrence Can Be Controlled By Rofecoxib 4Health News:Bacteria Can Survive In Extreme Heat 2
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
... Drug Discovery, Biotechnology, Genomic and ... special Quality Control over Sample Preparation ... an advanced benchtop ventilated centrifuge accommodates ... high capacity production throughput. High throughput ...
... A common sight in laboratories everywhere, ... rugged, dependable centrifuge standards for decades ... The Model K's simple, classic design ... it a standard for centrifuge performance, ...
Inquire...
Medicine Products: